polistes fuscatus venom protein

Polistes fuscatus venom protein is an allergenic extract derived from the venom of the northern paper wasp (*Polistes fuscatus*). It is indicated for the diagnosis and treatment of Hymenoptera venom hypersensitivity. As a diagnostic agent, it is used in skin testing (intradermal or prick) to identify IgE-mediated sensitivity in patients with a history of systemic reactions to wasp stings. As a therapeutic agent, it is used in venom immunotherapy (VIT) to reduce the risk of life-threatening systemic reactions (anaphylaxis) upon future stings. The extract contains major allergens such as phospholipase A1, hyaluronidase, and antigen 5. Immunotherapy works by inducing immunological tolerance, characterized by a shift from a Th2-mediated allergic response to a Th1/Treg-mediated response and the production of protective IgG "blocking" antibodies. It was approved by the FDA in 1992 (BLA 103971) and is marketed by companies such as Jubilant HollisterStier.

Brand names

Venomil

Other names

Northern paper wasp venomWasp venom proteinPolistes fuscatus venom extract